期刊文献+

盐酸拓扑替康联合顺铂治疗晚期非小细胞肺癌24例的疗效观察

下载PDF
导出
摘要 目的观察拓扑替康联合顺铂治疗晚期非小细胞肺癌的临床疗效及毒性反应。方法观察组24例,使用拓朴替康联合顺铂治疗;对照组22例,使用EP、CAP方案治疗,至少用药2个周期,随访观察6个月后对比疗效。结果观察组有效率29.17%,对照组有效率18.18%,差异无统计学意义(χ2=2.46,P=0.45);观察组血液系统毒性反应发生率高于对照组,但差异无统计学意义(P>0.05),两组胃肠道反应相似,肝、肾功能损害不明显。结论观察组治疗晚期非小细胞肺癌有一定疗效,毒性反应可以耐受,可作为二线药物临床使用。
出处 《广西医学》 CAS 2007年第10期1520-1521,共2页 Guangxi Medical Journal
  • 相关文献

参考文献7

二级参考文献24

  • 1潘启超.新抗癌药——紫杉醇的药理及临床疗效[J].癌症,1994,13(6):553-557. 被引量:16
  • 2[1]Schiller JH. Influential papers since the last IASLC conference: cytotoxic therapy. Lung Cancer,2003,41(Suppl 3)∶S86.
  • 3[2]Socinski MA. Optimal number of cytotoxic agents and chemotherapy cycles for advanced NSCLC. Lung Cancer,2003, 41(Suppl 3)∶S93.
  • 4[3]Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol,2001,19(5)∶1336-1343.
  • 5[4]Socinski MA, Schell MJ, Peterman A, et al. Phase Ⅲ trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage ⅢB/Ⅳ non-small-cell lung cancer. J Clin Oncol,2002,20(5)∶1335-1343.
  • 6[5]Depierre A, Quoix E, Mercier M, et al. Maintenance chemotherapy in advanced non-small cell lung cancer (NSCLC): A randomized study of vinorelbine (v) versus observation (ob) in patients (pts) responding to induction therapy (French Cooperative Oncology Group). Proc Am Soc Clin Onc,2001,20p∶309a.
  • 7[6]Fukuoka M. Epidermal growth factor receptor tyrosine kinase inhibitors: single agent therapy. Lung Cancer,2003,41(Suppl 3)∶S38.
  • 8[7]Goss G. Gefitinib ("Iressa"): The patients' experience. Lung Cancer,2003,41(Suppl 3)∶112.
  • 9[8]Herbst RS. Targeting the EGFR: prognostic and clinical implications. Lung Cancer,2003,41(Suppl 3)∶S114.
  • 10[9]Lynch T. Clinical benefit in NSCLC: The evidence for gefitinib ("Iressa"). Lung Cancer,2003,41(Suppl 3)∶S116.

共引文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部